Ignite Creation Date:
2025-12-24 @ 7:56 PM
Ignite Modification Date:
2026-01-06 @ 2:04 PM
Study NCT ID:
NCT06475404
Status:
COMPLETED
Last Update Posted:
2024-07-03
First Post:
2024-06-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016532', 'term': 'Mucopolysaccharidosis II'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009083', 'term': 'Mucopolysaccharidoses'}, {'id': 'D016464', 'term': 'Lysosomal Storage Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D040181', 'term': 'Genetic Diseases, X-Linked'}], 'ancestors': [{'id': 'D038901', 'term': 'X-Linked Intellectual Disability'}, {'id': 'D008607', 'term': 'Intellectual Disability'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D002239', 'term': 'Carbohydrate Metabolism, Inborn Errors'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D017520', 'term': 'Mucinoses'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 18}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-04-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'completionDateStruct': {'date': '2023-09-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-28', 'studyFirstSubmitDate': '2024-06-20', 'studyFirstSubmitQcDate': '2024-06-20', 'lastUpdatePostDateStruct': {'date': '2024-07-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-06-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of participants with Adverse Events', 'timeFrame': 'Day 28', 'description': 'Adverse events, Laboratory tests, Vital signs, Physical examination, 12-lead electrocardiogram, Allergic reactions, Infusion reactions, Antidrug antibody'}], 'secondaryOutcomes': [{'measure': 'Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Day 4', 'description': 'Analysis of equivalence of area under concentration-time curve from time 0 (predose) to the last quantifiable data point and to infinity'}, {'measure': 'Pharmacokinetics: Peak Plasma Concentration (Cmax)', 'timeFrame': 'Day 4', 'description': 'Analysis of equivalence of Cmax'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Mucopolysaccharidosis type II', 'Mucopolysaccharidoses', 'Metabolic Diseases', 'Lysosomal Storage Diseases', 'Carbohydrate Metabolism', 'Inborn', 'Metabolism', 'Genetic Diseases', 'Neurobehavioral Manifestations', 'Neurologic Manifestations', 'Genetic Diseases, X-Linked'], 'conditions': ['Mucopolysaccharidosis Type II', 'Metabolic Diseases']}, 'descriptionModule': {'briefSummary': 'It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers', 'detailedDescription': 'GNR-055 (verenafusp alfa) is intended for enzyme replacement therapy (ERT) in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a lysosomal storage disease with an X-linked recessive inheritance type, which is characterized by a decrease in the activity of the lysosomal enzyme iduronate-2-sulfatase (I2S), caused by a mutation in the idursulfase (IDS) gene. Enzyme deficiency leads to the accumulation of glycosaminoglycans (GAG) in lysosomes, mainly fractions of heparan and dermatan sulfates. Because of the insufficient activity of iduronate sulfatase participating in the first stage of catabolism of GAG, they accumulate in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.\n\nGNR 055 (verenafusp alfa) is a modified enzyme I2S capable of penetrating the blood-brain barrier and thus it is expected to prevent neurodegenerative consequences and the development of cognitive deficit in the future that will allow achieving a significant improvement in the life quality and expectancy of patients with MPS II.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'genderBased': True, 'genderDescription': 'As a rule, boys suffer from Mucopolysaccharidosis type II', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Men aged 18 to 45 years (inclusive) at the time of signing the Informed Consent Form;\n* Body mass index (BMI) 18.5 to 29.9 kg/m2, body weight of 50 to 90 kg;\n* A verified diagnosis as "healthy" (the diagnosis "healthy" is established based on a detailed medical history, in the absence of deviations from normal values during a clinical examination, including measurement of blood pressure, respiratory rate, heart rate, body temperature, laboratory and instrumental (ECG) examination data);\n* A written informed consent to participate in the study in accordance with applicable laws in place and compliance with all the procedures and requirements/restrictions provided for by the study protocol;\n* Consent to use adequate methods of contraception (double barrier method-male or female (for partners of male research volunteers), condom with spermicide, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, cervical cap with spermicide).\n\nExclusion Criteria:\n\n* Known hypersensitivity to idursulfase and/or to the medicinal product excipients;\n* Burdened allergy history;\n* Drug intolerance;\n* History of seizures;\n* Deposit injections or implants use of any other medicinal product three months before the Screening Visit;\n* An unusual way of living (night working, extreme physical activity);\n* Diarrhea dehydration, vomiting, or other causes within 24 hours before the Screening Visit;\n* Deviations from the normal values of the clinical, laboratory, and ECG examinations;\n* If there are acute or chronic diseases of the cardiovascular, bronchopulmonary, nervous, immune, and endocrine systems, diseases of the gastrointestinal tract, liver and biliary tract, kidney and urinary tract, blood and lymphatic system, a history of mental illness;\n* Positive results for hepatitis B or C markers, human immunodeficiency virus (HIV), and syphilis;\n* Acute infectious diseases less than four weeks before the Screening Visit;\n* Regular administration of medicinal products less than two weeks before the Screening Visit;\n* Systolic blood pressure (SBP) below 90 mm Hg or above 139 mm Hg; diastolic blood pressure (DBP) below 50 mm Hg or above 89 mm Hg; heart rate (HR) below 60 bpm or above 90 bpm;\n* Blood donation (450 mL or more of blood or plasma) less than three months before the Screening Visit;\n* Participation in human clinical studies of medicinal products less than three months before the Screening Visit;\n* Consumption of more than 5 units of alcohol per week (1 unit of alcohol is equal to 30 ml of ethyl alcohol) OR history of alcoholism, drug addiction, or drug abuse;\n* Alcohol exhale positive test;\n* Drug addiction and positive urine analysis for potent and narcotic substances;\n* Smoking more than 5 cigarettes per day;\n* Any planned surgical intervention during the study period;\n* Reluctance to comply with contraceptive methods;\n* Vaccination (with any vaccine) within 30 days before signing the informed consent and/or the need for vaccination during the study period; 23. History of an autoimmune disease; 24. History of any cancer.'}, 'identificationModule': {'nctId': 'NCT06475404', 'briefTitle': 'A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'AO GENERIUM'}, 'officialTitle': 'Open-label Multi-cohort Study of the Tolerability, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers After a Single Intravenous Injection in Increasing Doses', 'orgStudyIdInfo': {'id': 'IDB-MPS-I02'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'verenafusp alfa 6 mg/kg intravenously', 'description': 'Single intravenous administration', 'interventionNames': ['Biological: verenafusp alfa 6 mg/kg']}, {'type': 'EXPERIMENTAL', 'label': 'verenafusp alfa 9 mg/kg intravenously', 'description': 'Single intravenous administration', 'interventionNames': ['Biological: verenafusp alfa 9 mg/kg']}, {'type': 'EXPERIMENTAL', 'label': 'verenafusp alfa 12 mg/kg intravenously', 'description': 'Single intravenous administration', 'interventionNames': ['Biological: verenafusp alfa 12 mg/kg']}], 'interventions': [{'name': 'verenafusp alfa 6 mg/kg', 'type': 'BIOLOGICAL', 'otherNames': ['GNR-055'], 'description': 'Single intravenous administration of 6 mg/kg of verenafusp alfa', 'armGroupLabels': ['verenafusp alfa 6 mg/kg intravenously']}, {'name': 'verenafusp alfa 9 mg/kg', 'type': 'BIOLOGICAL', 'otherNames': ['GNR-055'], 'description': 'Single intravenous administration of 9 mg/kg of verenafusp alfa', 'armGroupLabels': ['verenafusp alfa 9 mg/kg intravenously']}, {'name': 'verenafusp alfa 12 mg/kg', 'type': 'BIOLOGICAL', 'otherNames': ['GNR-055'], 'description': 'Single intravenous administration of 12 mg/kg of verenafusp alfa', 'armGroupLabels': ['verenafusp alfa 12 mg/kg intravenously']}]}, 'contactsLocationsModule': {'locations': [{'zip': '117556', 'city': 'Moscow', 'country': 'Russia', 'facility': 'State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department"', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}], 'overallOfficials': [{'name': 'Oksana A. Markova, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'JSC GENERIUM'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AO GENERIUM', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}